Jazz Pharmaceuticals plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Jazz Pharmaceuticals plc (JAZZ) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $963.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-24
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $963.00K.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2011 was $353.00K.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2010 was -$80.00K, a 125.32% decline from fiscal 2009.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2009 was $316.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $963.00K 10-K · filed 2026-02-24 |
| 2011-12-31 | $353.00K 10-K · filed 2012-02-28 |
| 2010-12-31 | -$80.00K 10-K · filed 2012-02-28 |
| 2009-12-31 | $316.00K 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |